The Goldman Sachs Group Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its target price boosted by equities research analysts at The Goldman Sachs Group from $1,260.00 to $1,283.00 in a note issued to investors on Friday,MarketScreener reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 31.16% from the company’s current price.

A number of other equities research analysts have also issued reports on LLY. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 6th. Loop Capital set a $1,200.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Zacks Research lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Bank of America increased their price target on shares of Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Finally, Argus raised their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,218.30.

Eli Lilly and Company Stock Up 4.7%

Shares of LLY opened at $978.18 on Friday. The stock has a 50 day moving average price of $947.05 and a 200 day moving average price of $984.98. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock has a market capitalization of $924.21 billion, a price-to-earnings ratio of 42.66, a PEG ratio of 1.00 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 33.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares during the last quarter. State Street Corp increased its holdings in Eli Lilly and Company by 1.8% in the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after purchasing an additional 635,358 shares during the last quarter. Capital Research Global Investors raised its position in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. Morgan Stanley raised its position in Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after purchasing an additional 407,166 shares during the period. Finally, Capital World Investors lifted its stake in Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly crushed Q1 estimates and raised full‑year guidance — strong GLP‑1 volume drove 56% revenue growth and management boosted FY26 revenue and EPS targets, a primary catalyst for the stock lift. Eli Lilly crushes Q1 estimates, raises full-year outlook
• Positive Sentiment: Foundayo oral GLP‑1 pill is already reaching patients (CEO: >20,000 prescriptions early), supporting upside to the obesity pill opportunity and long‑term GLP‑1 adoption. Lilly’s weight loss pill reaches brand new patients
• Positive Sentiment: FDA proposed excluding active ingredients for tirzepatide/semaglutide from bulk compounding — could limit cheaper compounded competitors and protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Market commentary and upgrades: analysts and investors upgraded/touted LLY after the print (Seeking Alpha upgrade, Guggenheim PT raise), reinforcing buy-side interest. Eli Lilly: Buying Opportunity (Rating Upgrade)
• Neutral Sentiment: Corporate activity supports pipeline expansion — acquisition of Ajax (JAK inhibitors) and a $2.25B AI/gene‑editing partnership broaden long‑term growth drivers but are multi‑year value creators. Why Eli Lilly is One of the Best Drug Stocks
• Neutral Sentiment: Summaries/transcripts of the earnings call and analyst notes provide color (Moby, Seeking Alpha transcript) for investors assessing sustainability of volume vs. pricing trends. Eli Lilly Q1 2026 Earnings Call Summary
• Negative Sentiment: Competition and mixed early pill metrics: social/industry notes point to a slower Foundayo launch vs. competitors in week‑to‑week scripts, and Novo remains a strong rival — this could cap near‑term share gains. Opinions on Foundayo Pill Launch
• Negative Sentiment: Valuation and selling activity: coverage notes call LLY an expensive stock even as some investors and insiders have been selling; high multiples raise sensitivity to any slowdown in GLP‑1 momentum. Valuation commentary from Gary Black

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.